Matthew W. Foehr
2016 - Ligand Pharmaceuticals
In 2016, Matthew W. Foehr earned a total compensation of $2.8M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 15% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $193,181 |
|---|---|
| Option Awards | $1,169,942 |
| Salary | $429,292 |
| Stock Awards | $973,888 |
| Other | $74,954 |
| Total | $2,841,257 |
Foehr received $1.2M in option awards, accounting for 41% of the total pay in 2016.
Foehr also received $193.2K in non-equity incentive plan, $429.3K in salary, $973.9K in stock awards and $75K in other compensation.
Rankings
In 2016, Matthew W. Foehr's compensation ranked 3,405th out of 14,075 executives tracked by ExecPay. In other words, Foehr earned more than 75.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,405 out of 14,075 | 76th |
Division Manufacturing | 1,185 out of 5,486 | 78th |
Major group Chemicals And Allied Products | 358 out of 1,900 | 81st |
Industry group Drugs | 259 out of 1,543 | 83rd |
Industry Pharmaceutical Preparations | 203 out of 1,173 | 83rd |
Source: SEC filing on April 14, 2017.
Foehr's colleagues
We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2016.